Future & Tech Corp

Future & Tech is a South Korean biopharmaceutical company specializing in the development of next-generation active immunotherapies for human and veterinary applications. Founded in 2018, the company utilizes its proprietary GOST (GRAS μ-Organism Surface-display Technique) platform to engineer GRAS-grade microorganisms, such as Lactobacillus paracasei, to express target antigens on their cell surfaces. This technology enables the development of cost-effective, orally administered vaccines and therapeutics that induce active immune responses against self-proteins and viral targets. The company's pipeline focuses on muscle-related disorders like sarcopenia and muscular dystrophy by targeting myostatin (GDF-8), as well as cancer immunotherapy and metabolic diseases. Future & Tech is headquartered in Daejeon and actively collaborates with academic and research institutions to advance its microbial-based drug delivery systems.